Literature DB >> 2543557

Potentiation of kainic acid epileptogenicity and sparing from neuronal damage by an NMDA receptor antagonist.

R G Fariello1, G T Golden, G G Smith, P F Reyes.   

Abstract

The time course and severity of the excitotoxic syndrome induced in rats by s.c. injection of 10 mg/kg kainic acid (KA) was modified by pretreatment with MK801, a non-competitive inhibitor of the NMDA receptor, at doses of 0.1, 1 and 10 mg/kg. A dose-dependent increase in the severity of the KA-induced electrographic (EEG) manifestations of epilepsy was seen after MK801. This consisted of an earlier appearance and higher number of EEG seizures, longer time spent in seizures, and an earlier onset of status epilepticus. In contrast, behavioral seizures were increased only in the 0.1 mg/kg MK801 group, but abolished by higher doses. On the contrary, wet dog shakes were progressively reduced with increasing doses of MK801. Four of the 9 animals receiving KA-only group and 3 of the 10 animals in the 1 and 10 mg MK801 groups were sacrificed 5 days after KA. The brain of the KA-only rats presented diffuse gross and microscopic evidence of hemorrhagic necrosis and neuronal damage; the MK801 rats showed only minimal neuronal loss in the CA3 hippocampal sector. This study demonstrates that neuronal damage and epileptiform activity can be dissociated. Furthermore, it confirms the protective effect of MK801 against neuronal damage caused by multiple factors. Lastly, it emphasizes the need for EEG monitoring in order to accurately assess any epileptic/antiepileptic effect.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2543557     DOI: 10.1016/0920-1211(89)90025-9

Source DB:  PubMed          Journal:  Epilepsy Res        ISSN: 0920-1211            Impact factor:   3.045


  14 in total

1.  Neuroprotection by glutamate receptor antagonists against seizure-induced excitotoxic cell death in the aging brain.

Authors:  P Elyse Schauwecker
Journal:  Exp Neurol       Date:  2010-03-29       Impact factor: 5.330

2.  Role of kynurenines in the neurotoxic actions of kainic acid.

Authors:  W M Behan; T W Stone
Journal:  Br J Pharmacol       Date:  2000-04       Impact factor: 8.739

3.  Ketamine controls prolonged status epilepticus.

Authors:  D J Borris; E H Bertram; J Kapur
Journal:  Epilepsy Res       Date:  2000-12       Impact factor: 3.045

4.  A novel non-transcriptional pathway mediates the proconvulsive effects of interleukin-1beta.

Authors:  Silvia Balosso; Mattia Maroso; Manuel Sanchez-Alavez; Teresa Ravizza; Angelisa Frasca; Tamas Bartfai; Annamaria Vezzani
Journal:  Brain       Date:  2008-10-24       Impact factor: 13.501

5.  Mediation of the neuroprotective action of R-phenylisopropyl-adenosine through a centrally located adenosine A1 receptor.

Authors:  D G MacGregor; W J Miller; T W Stone
Journal:  Br J Pharmacol       Date:  1993-09       Impact factor: 8.739

6.  A comparison of three NMDA receptor antagonists in the treatment of prolonged status epilepticus.

Authors:  Weiwei Yen; John Williamson; Edward H Bertram; Jaideep Kapur
Journal:  Epilepsy Res       Date:  2004-03       Impact factor: 3.045

7.  Inhibition by the adenosine analogue, (R-)-N6-phenylisopropyladenosine, of kainic acid neurotoxicity in rat hippocampus after systemic administration.

Authors:  D G MacGregor; T W Stone
Journal:  Br J Pharmacol       Date:  1993-06       Impact factor: 8.739

8.  The in vivo proconvulsant effects of corticotropin releasing hormone in the developing rat are independent of ionotropic glutamate receptor activation.

Authors:  K L Brunson; L Schultz; T Z Baram
Journal:  Brain Res Dev Brain Res       Date:  1998-11-01

9.  Drug refractory epilepsy in brain damage: effect of dextromethorphan on EEG in four patients.

Authors:  B Schmitt; R Netzer; S Fanconi; P Baumann; E Boltshauser
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-03       Impact factor: 10.154

10.  Fos protein induction, neuropathology, and pharmacological protection after excitotoxic brain insult.

Authors:  E Ciani; T Guarnieri; A Contestabile
Journal:  Exp Brain Res       Date:  1994       Impact factor: 1.972

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.